Cargando…
Is an EAA > 0.6 in severe COVID-19 patients synonymous with a toxic and pro-inflammatory endotoxin profile, and should we treat it?
Autores principales: | Honore, Patrick M., Redant, Sebastien, De Bels, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987113/ https://www.ncbi.nlm.nih.gov/pubmed/33759006 http://dx.doi.org/10.1186/s40635-021-00376-w |
Ejemplares similares
-
Eliminating endotoxin by polymyxin B hemoperfusion and/or continuous renal replacement therapy: should the focus be on timing, dosing, and type of renal epuration?
por: Honore, Patrick M., et al.
Publicado: (2019) -
Early Prediction of Acute Kidney Injury by Machine Learning: Should We Add the Urine Output Criterion to Improve this New Tool?
por: Martins, Cyril Busschots, et al.
Publicado: (2020) -
Obesity inducing acute respiratory distress syndrome: we should choose the right population!
por: Honore, Patrick M., et al.
Publicado: (2019) -
Ketoacidosis in type 1 diabetics: we should return to pediatric guidelines
por: Redant, Sébastien, et al.
Publicado: (2020) -
Efficacy of polymyxin B hemoperfusion in and beyond septic shock: is an “endotoxin severity score” needed?
por: Honore, Patrick M., et al.
Publicado: (2018)